Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 2 - You Need To See This

This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment

Biogen Inc. (NASDAQ:BIIB) on Thursday agreed to acquire Massachusetts-based Alcyone Therapeutics for $85 million.

Benzinga

Is Biogen Stock Underperforming the Nasdaq?

Although Biogen has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy

The U.S. Food and Drug Administration (FDA) stated on Thursday that it is requiring an additional MRI scan for Alzheimer's patients receiving Leqembi (lecanemab), citing safety concerns over a rare but potentially fatal side effect.

Benzinga

Biogen Stock: Analyst Estimates & Ratings

Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Barchart

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

Benzinga

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Benzinga

Here's What to Expect From Biogen's Next Earnings Report

Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline.

Barchart

Earnings Preview: What To Expect From Biogen's Report

Biogen is poised to announce its first-quarter results next month, and analysts predict a single-digit dip in the company’s bottom-line figure.

Barchart

European regulators OK Alzheimer's treatment Leqembi after initial doubts

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer

The Independent UK

Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

Barchart

How Is Biogen's Stock Performance Compared to Other Biotech Stocks?

Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects.

Barchart

Biogen Stock Outlook: Is Wall Street Bullish or Bearish?

Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%

These biotech companies are poised for significant long-term growth. However, there are risks.

MarketBeat

Biogen Stock Is Mutating Into a Value Play

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Barchart

Stocks Settle Mixed as Chip Stock Strength Lifts the Nasdaq

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.12%. March E-mini S&P futures (ESH25 ) are down by -0.29%, and March E-mini Nasdaq...

Barchart

Stocks Tumble as Sticky US Inflation Keeps Fed on Hold

The S&P 500 Index ($SPX ) (SPY ) today is down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.32%. March E-mini S&P futures (ESH25 ) are down by -0.48%, and March E-mini Nasdaq...

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stocks Sink and Bond Yields Spike on Strong CPI

The S&P 500 Index ($SPX ) (SPY ) today is down -0.91%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.92%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.89%. March E-mini S&P futures (ESH25 ) are down by -0.87%, and March E-mini Nasdaq...

Barchart

Biogen's Quarterly Earnings Preview: What You Need to Know

Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line.

Barchart

Biogen Stock: Is BIIB Underperforming the Healthcare Sector?

Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential.

Benzinga

Assessing Biogen: Insights From 19 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 19 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months.

StockNews.com

3 Biotech Stocks with Promising Pipelines to Watch

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

The Independent UK

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

Barchart

Biogen's Q3 2024 Earnings: What to Expect

Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.